Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Glycorex Transplantation AB (publ)
  6. News
  7. Summary
    GTAB B   SE0000524530

GLYCOREX TRANSPLANTATION AB (PUBL)

(GTAB B)
  Report
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Glycorex Transplantation AB Announces Presentation of results at the SABM 2021 Annual Meeting

09/24/2021 | 11:15am EST

Glycorex Transplantation AB (publ.) announced that the Transfusion unit at the University of Rochester Medical Center presents their experience with the UBP-product for the manufacturing of low titer-blood group O whole blood (LTOWB) at the Society for the Advancement of Blood Management (SABM) on September 24, 2021. The company has developed a CE-marked medical device for reduction of blood group A and blood group B specific antibodies (UBP-product). Massive bleeding is one of the leading causes of death in severe trauma. Evidence is growing suggesting that transfusion of whole blood is most appropriate in this setting, however the availability of blood group O whole blood with low levels (titers) of blood group antibodies (anti-A/B antibodies) is limited. Thus, products or methods for the manufacturing of LTOWB for use in massive transfusion may prove to be of significant clinical value in both civilian and military contexts. The company's UBP-product has been tested at the University of Rochester Medical Center (U.S.) for this very purpose: to reduce anti-A/B antibody titers in blood group O whole blood. The results are encouraging as they show that the UBP-product is effective in reducing anti-A/B antibody titers in whole blood units to near zero, without effecting other blood parameters as tested by the complete blood count or thromboelastography assays.


ę S&P Capital IQ 2021
All news about GLYCOREX TRANSPLANTATION AB (PUBL)
11/02GLYCOREX TRANSPLANTATION AB : Geert Nygaard appointed asánew CEO
AQ
11/02Glycorex Transplantation AB Appoints Geert Nygaard as CEO
CI
09/24MANUFACTURING OF LOW TITER-BLOOD GRO : Presentation of results at the SABM 2021 Annual Mee..
AQ
09/24Glycorex Transplantation AB Announces Presentation of results at the SABM 2021 Annual M..
CI
09/22UBP PRODUCT : Presentation of results at the Jahrestagung DGTI
AQ
09/22Glycorex Transplantation AB Announces Presentation of Results at the Jahrestagung DGFTI
CI
08/25GLYCOREX TRANSPLANTATION AB (GTAB) : Interim Report April-June 2021
AQ
08/25Glycorex Transplantation AB Announces Earnings Results for the Second Quarter and Six M..
CI
07/19GLYCOREX TRANSPLANTATION AB (GTAB B) : Universal Whole Blood: Presentation of results at t..
AQ
06/15GLYCOREX TRANSPLANTATION : Publication shows significant benefits of using intraoperative ..
AQ
More news
Financials
Sales 2020 28,6 M 3,13 M 3,13 M
Net income 2020 -8,04 M -0,88 M -0,88 M
Net cash 2020 40,0 M 4,37 M 4,37 M
P/E ratio 2020 -105x
Yield 2020 -
Capitalization 690 M 75,4 M 75,4 M
EV / Sales 2019 18,3x
EV / Sales 2020 28,3x
Nbr of Employees 20
Free-Float 95,6%
Chart GLYCOREX TRANSPLANTATION AB (PUBL)
Duration : Period :
Glycorex Transplantation AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Johan Nilsson Chief Executive Officer
Kurt G÷sta Ingemar Nilsson Chairman & Development Director
Nils Siegbahn Director
Christer Ahlberg Director
Leni von Bonsdorff Director